-+ 0.00%
-+ 0.00%
-+ 0.00%
AstraZeneca: ZEGFROVY is now available in the US to treat previously treated patients with non-small cell lung cancer with EGFR exon 20 insertion mutations.
Share
Listen to the news
AstraZeneca: ZEGFROVY is now available in the US to treat previously treated patients with non-small cell lung cancer with EGFR exon 20 insertion mutations.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending